{
  "hash": "78c71a1f96545c1f048fa277d8e97077",
  "result": {
    "engine": "knitr",
    "markdown": "---\neditor_options: \n   chunk_output_type: console\n---\n\n\n\n# ACA Federal Upper Limits {#sec-acaful}\n\n__Affordable Care Act Federal Upper Limits (FUL)__ based on the weighted average of the most recently reported monthly __average manufacturer price (AMP)__ for pharmaceutical and therapeutically equivalent multiple source drug products that are available for purchase by retail community pharmacies on a nationwide basis.\n\n## Metadata\n\n\n::: {.cell layout-align=\"center\"}\n<pre class=\"r-output\"><code>  [ROWS] 1965434 \n [PAGES] 246 \n[FIELDS] 14 \n</code></pre>\n:::\n\n\n### Dictionary\n\n\n::: {.cell layout-align=\"center\"}\n<pre class=\"r-output\"><code><span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>product_group</span>\n<span style='color: #555555;'>The following methodology forms a Product Group:\nInclude all innovator (I) and non-innovator (N)\npharmaceutically and therapeutically equivalent\n(A-rated) multiple source drugs when calculating\nthe weighted average of monthly AMPs in a FUL\nProduct Group; Will not include single source\n(S) drugs when calculating the weighted average\nof monthly AMPs in a FUL Product Group; Will\nnot include formulations of the drug that are\nnot rated by the FDA as pharmaceutically and\ntherapeutically equivalent to the reference listed\ndrug, (A-rated) in the calculation of the weighted\naverage of monthly AMPs, or apply the FUL to\nthose formulations that are not A-rated, e.g.,\nB-rated drugs; Will use the monthly AMP and AMP\nunits reported and certified by manufacturers to\ncalculate the weighted average of monthly AMPs in\na FUL Product Group; and, Will not include the AMP\nof a terminated drug in the weighted average of\nmonthly AMPs.</span>\n\n<span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>ingredient</span>\n<span style='color: #555555;'>The order of ingredients presented in the product\nlabeleling.</span>\n\n<span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>strength</span>\n<span style='color: #555555;'>The strengths presented in the product labeleling.</span>\n\n<span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>dosage</span>\n<span style='color: #555555;'>The dosage form of the drug.</span>\n\n<span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>route</span>\n<span style='color: #555555;'>The route of administration of the drug.</span>\n\n<span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>mdr_unit_type</span>\n<span style='color: #555555;'>The unit type reported to the CMS Medicaid Drug\nRebate Program.</span>\n\n<span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>weighted_average_amps</span>\n<span style='color: #555555;'>The calculated weighted average of the monthly\namps for the group.</span>\n\n<span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>aca_ful</span>\n<span style='color: #555555;'>The calculated Federal Upper Limit (FUL) for the\ngroup.</span>\n\n<span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>package_size</span>\n<span style='color: #555555;'>Identifies the number of billing units in the\npackage quantity from which the pharmacist\ndispenses.</span>\n\n<span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>ndc</span>\n<span style='color: #555555;'>The National Drug Code (NDC) is a numerical code\nmaintained by the FDA that includes the labeler\ncode, product code, and package code.</span>\n\n<span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>arated</span>\n<span style='color: #555555;'>Identifies if the drug is an A-rated drug, (Yes or\nNo).</span>\n\n<span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>multiplier_greater_than_175_percent_of_weighted_avg_of_amps</span>\n<span style='color: #555555;'>ACA FUL equals the most current average retail\ncommunity pharmacies' acquisition cost (NADAC)\n= Y ACA FUL equals 175 percent of the weighted\naverage of the most recently reported monthly\nAMPs = N Note: All NDC-11s for a FUL Product Group\nare included in this file; however, only the (I)\nand (N), A-rated, multiple source drugs are used\nto calculate the weighted average of the most\nrecently reported monthly AMPs in a FUL Product\nGroup.</span>\n\n<span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>year</span>\n<span style='color: #555555;'>The year in which the FUL was calculated.</span>\n\n<span style='color: #BB0000; font-weight: bold; text-decoration: underline;'>month</span>\n<span style='color: #555555;'>The month in which the FUL was calculated.</span>\n</code></pre>\n:::\n\n\n## Data\n\n\n::: {.cell layout-align=\"center\"}\n<pre class=\"r-output\"><code><span style='color: #555555;'># A tibble: 8,000 × 14</span>\n   product_group ingredient      strength dosage route mdr_unit_type\n   <span style='color: #555555; font-style: italic;'><chr></span>         <span style='color: #555555; font-style: italic;'><chr></span>           <span style='color: #555555; font-style: italic;'><chr></span>    <span style='color: #555555; font-style: italic;'><chr></span>  <span style='color: #555555; font-style: italic;'><fct></span> <span style='color: #555555; font-style: italic;'><fct></span>        \n<span style='color: #555555;'> 1</span> 1165          NYSTATIN        500000U  TABLET ORAL  TAB          \n<span style='color: #555555;'> 2</span> 4486          OLMESARTAN MED… 20MG     TABLET ORAL  TAB          \n<span style='color: #555555;'> 3</span> 2662          RIVASTIGMINE T… 3MG      CAPSU… ORAL  CAP          \n<span style='color: #555555;'> 4</span> 1912          QUINAPRIL HYDR… 5MG      TABLET ORAL  TAB          \n<span style='color: #555555;'> 5</span> 8824          MONTELUKAST SO… 10MG     TABLET ORAL  TAB          \n<span style='color: #555555;'> 6</span> 3457          METFORMIN HCL   1000 MG  TABLET ORAL  TAB          \n<span style='color: #555555;'> 7</span> 3930          TOLTERODINE TA… 4 MG     CAP E… ORAL  CAP          \n<span style='color: #555555;'> 8</span> 1887          DILTIAZEM HYDR… 360MG    CAPSU… ORAL  CAP          \n<span style='color: #555555;'> 9</span> 1938          FENOFIBRATE     134MG    CAPSU… ORAL  CAP          \n<span style='color: #555555;'>10</span> 857           INDAPAMIDE      2.5MG    TABLET ORAL  TAB          \n<span style='color: #555555;'># ℹ 7,990 more rows</span>\n<span style='color: #555555;'># ℹ 8 more variables: aca_ful <dbl>, package_size <int>, ndc <chr>,</span>\n<span style='color: #555555;'>#   arated <int>, year <int>, month <int>, amp_wt_avg <dbl>,</span>\n<span style='color: #555555;'>#   gt_175pc_amp_wt_avg <int></span>\n</code></pre><pre class=\"r-output\"><code>obs: 8000 \ncols: 14 \n\n----- Numeric -----\n             col n_missng p_complt n_unique    mean        p0\n1        aca_ful        0        1     1234    1.43    0.0033\n2   package_size        0        1       71  227.45         1\n3         arated        0        1        2    0.99         0\n4           year        0        1        1    2019      2019\n5          month        0        1        2       2         2\n6     amp_wt_avg        0        1     1235    0.75    0.0019\n7 gt_175pc_mp_w_        0        1        2    0.38         0\n       p25     p50     p75    p100   iqr      sd  hist\n1    0.099    0.25    0.84   127.3  0.74    5.56 ▇▁▁▁▁\n2       30     100     100   28000    70  557.17 ▇▁▁▁▁\n3        1       1       1       1     0   0.094 ▁▁▁▁▇\n4     2019    2019    2019    2019     0       0 ▁▁▇▁▁\n5        2       2       2      11     0    0.17 ▇▁▁▁▁\n6    0.049    0.12    0.42    72.7  0.37    3.08 ▇▁▁▁▁\n7        0       0       1       1     1    0.48 ▇▁▁▁▅\n\n----- Categorical -----\n            col n_missng p_complt n_unique n_levels\n1 product_group        0        1     1237       NA\n2    ingredient        0        1      466       NA\n3      strength        0        1      389       NA\n4        dosage        0        1       66       NA\n5         route        0        1       14       14\n6 mdr_unit_type        0        1        6        6\n7           ndc        0        1     8000       NA\n               min           max\n1            10036           992\n2 ABACAVIR SULFATE    ZONISAMIDE\n3       .025MG/24H          90MG\n4       ADH. PATCH          VIAL\n5           DENTAL       VAGINAL\n6              CAP           TDP\n7    00002-3231-30 99207-0010-10\n</code></pre>\n:::\n\n\n### Distribution\n\n\n::: {.cell layout-align=\"center\"}\n<pre class=\"r-output\"><code>Variable            |    Mean |     SD |   IQR |              Range\n-------------------------------------------------------------------\naca_ful             |    1.43 |   5.56 |  0.74 | [3.28e-03, 127.26]\npackage_size        |  227.45 | 557.17 | 70.00 |   [1.00, 28000.00]\narated              |    0.99 |   0.09 |  0.00 |       [0.00, 1.00]\nyear                | 2019.00 |   0.00 |  0.00 | [2019.00, 2019.00]\nmonth               |    2.00 |   0.17 |  0.00 |      [2.00, 11.00]\namp_wt_avg          |    0.75 |   3.08 |  0.37 |  [1.87e-03, 72.72]\ngt_175pc_amp_wt_avg |    0.38 |   0.48 |  1.00 |       [0.00, 1.00]\n\nVariable            | Skewness | Kurtosis |    n | n_Missing\n------------------------------------------------------------\naca_ful             |    13.10 |   236.32 | 8000 |         0\npackage_size        |    21.21 |   849.35 | 8000 |         0\narated              |   -10.48 |   107.75 | 8000 |         0\nyear                |          |          | 8000 |         0\nmonth               |    51.62 |  2663.33 | 8000 |         0\namp_wt_avg          |    13.91 |   264.56 | 8000 |         0\ngt_175pc_amp_wt_avg |     0.51 |    -1.74 | 8000 |         0\n</code></pre>\n:::\n\n\n\n::: {.cell layout-ncol=\"2\" layout-align=\"center\"}\n::: {.cell-output-display}\n![](caid_acaful_files/figure-html/distribution_plot-1.png){fig-align='center' width=70%}\n:::\n\n::: {.cell-output-display}\n![](caid_acaful_files/figure-html/distribution_plot-2.png){fig-align='center' width=70%}\n:::\n\n::: {.cell-output-display}\n![](caid_acaful_files/figure-html/distribution_plot-3.png){fig-align='center' width=70%}\n:::\n\n::: {.cell-output-display}\n![](caid_acaful_files/figure-html/distribution_plot-4.png){fig-align='center' width=70%}\n:::\n\n::: {.cell-output-display}\n![](caid_acaful_files/figure-html/distribution_plot-5.png){fig-align='center' width=70%}\n:::\n\n::: {.cell-output-display}\n![](caid_acaful_files/figure-html/distribution_plot-6.png){fig-align='center' width=70%}\n:::\n\n::: {.cell-output-display}\n![](caid_acaful_files/figure-html/distribution_plot-7.png){fig-align='center' width=70%}\n:::\n:::\n\n",
    "supporting": [
      "caid_acaful_files"
    ],
    "filters": [
      "rmarkdown/pagebreak.lua"
    ],
    "includes": {},
    "engineDependencies": {},
    "preserve": {},
    "postProcess": true
  }
}